Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer’s Drug Safety Web Site Aims To Reclaim Risk Communication Authority

Executive Summary

BOSTON-Pfizer's new Medicine Safety Web site is the first attempt by a pharmaceutical company to reclaim authority over risk communication from FDA

You may also be interested in...

FDA Amendments Act Implementation Faces Delay; Agency To Miss Deadlines

FDA is expected to miss a spate of implementation deadlines for provisions of the FDA Amendments Act as the law approaches its first anniversary

Extra Caution Needed In Uncertain Period For Off-label Info Distribution

In off-label promotion investigations, OIG looks for kickback issues or other bad conduct and whether there is patient harm.

FDA List Of Potential Safety Signals Has 3 Pfizer Drugs, Echoes Drug Watch Site

FDA's quarterly report that lists potential signals of serious risks for drugs is similar in design to a program that the agency proposed and then withdrew following industry criticism

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts